Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Zhejiang Hongchang Electrical Technology
301008
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
CN Stock MarketDetailed Quotes
688177 Bio-Thera Solutions,
- 22.30
- -0.02-0.09%
Market Closed Apr 30 15:00 CST
9.23BMarket Cap-19.06P/E (TTM)
22.74High22.24Low15.87KlotVolume22.24Open22.32Pre Close35.58MTurnover0.38%Turnover RatioLossP/E (Static)414.08MShares35.7852wk High15.02P/B9.23BFloat Cap17.7052wk Low26.78Limit Up414.08MShs Float78.00Historical High17.86Limit Down2.24%Amplitude17.09Historical Low--Dividend TTM22.42Avg Price7.27KlotAsk--Div YieldTTM100Lot Size7.66KlotBid
Bio-Thera Solutions, News
Biotech: Biotech\'s 2025 First Quarter Report
Biotech\'s 2025 First Quarter Report
Bio-Thera Solutions (688177.SH) announced its first quarter performance, with a net loss attributable to shareholders of 93.331 million yuan, a reduced loss.
Bio-Thera Solutions (688177.SH) released its first-quarter report for 2025, with revenue of 2.07...
Bio-Thera Solutions (688177.SH) reported a revenue of 0.207 billion yuan in the first quarter, an increase of 27.83% compared to the same period last year.
Gelonghui reported on April 28 that Bio-Thera Solutions (688177.SH) announced that in the first quarter of 2025, the company's revenue was 0.207 billion yuan, an increase of 27.83% year-on-year; the net loss attributable to shareholders of the listed company was 93.33 million yuan, compared to a loss of 0.119 billion yuan in the same period last year; the basic EPS was -0.23 yuan/share.
Bio-Thera Solutions Gets Nod to Trial Advanced Tumor Drug
Bio-Thera Solutions (688177.SH): Injection BAT7111 has obtained the approval notification for clinical drug trials.
Gelonghui, April 21st, Bio-Thera Solutions (688177.SH) announced that the company recently received the "Approval Notice for Clinical Trials of Pharmaceuticals" issued by the National Medical Products Administration, and the clinical trial application for the investigational drug BAT7111 for advanced solid tumors has been approved. BAT7111 is a PD-1/4-1BB bispecific antibody developed by Bio-Thera Solutions, intended for the treatment of advanced solid tumors. 4-1BB (also known as CD137) is mainly expressed on activated CD8+ effector T cells and acts as a T-cell co-stimulatory molecule, maintaining immune homeostasis and resisting immune cell apoptosis.
Private Companies Are Bio-Thera Solutions, Ltd.'s (SHSE:688177) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥1.2b Last Week
Biotech: Biotech 2024 Annual Report Summary
Biotech: Biotech 2024 Annual Report
Biotech 2024 Annual Report Summary
Biotech 2024 Annual Report
Bio-Thera Solutions (688177.SH): Net loss of 0.51 billion yuan in 2024.
On April 8, Gelonghui reported that Bio-Thera Solutions (688177.SH) published its annual report for 2024, revealing revenue of 0.743 billion yuan, a year-on-year increase of 5.44%; the net income attributable to shareholders of the listed company was -0.51 billion yuan; basic EPS was -1.23 yuan. The main reason for the year-on-year revenue growth is the continuous increase in the sales of Guleli (Adalimumab) injection, along with the new overseas supply business for Tocilizumab injections; however, the overseas partners are still in the early stage of development, resulting in a relatively small overall increase in revenue.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Express News | Bio-Thera and DR. Reddy's Execute Exclusive Commercialization Agreement for Bat2206 and Bat2506
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Bio-Thera Solutions Obtains Acceptance of Marketing Authorization Application for Golimumab Injection
Further Weakness as Bio-Thera Solutions (SHSE:688177) Drops 4.4% This Week, Taking Five-year Losses to 61%
Biotech: Biotech 2024 Annual Results Report Announcement
Biotech 2024 Annual Results Report Announcement
Bio-Thera Solutions (688177.SH): net loss of 0.509 billion yuan for the year 2024.
On February 25, Gelonghui reported that Bio-Thera Solutions (688177.SH) disclosed its performance report for 2024. During the reporting period, the company achieved revenue of 0.743 billion yuan, a year-on-year increase of 5.44%; the net income attributable to the parent company was -0.509 billion yuan, and the net income attributable to the parent company after deducting non-recurring gains and losses was -0.554 billion yuan; the company's basic EPS was -1.23 yuan, and the weighted average return on net assets was -53.10%.
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. Do you think Buffett was scooping up stocks during the recent dip? 2. In the face of market changes, do you prefer to stick
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts